Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:12:39.773Z.
Calculation as of: 2026-10-06T19:12:39.773Z.
Quote observation: 2026-10-06T19:10:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 53f0b653117dfddf80d57e74ba570551200adc0db5709ea8e1a3c029d43ac92d
PEG RATIO
N/A
MBX Biosciences, Inc. Common Stock
Market Cap
$2.65B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.68B
PEG Ratio
N/A
TTM Avg
0.71
3Y Avg
2.28
5Y Avg
1.55
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MBX Biosciences, Inc. Common Stock (MBX) | $2.65B | N/A | N/A | N/A | N/A |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.65B | N/A | N/A | N/A | N/A |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.68B | N/A | 0.71 | 2.28 | 1.55 |
| Neogen Corporation (NEOG)vs › | $2.61B | N/A | 321.03 | 112.67 | 68.99 |
| Beam Therapeutics Inc. (BEAM)vs › | $2.60B | N/A | N/A | N/A | N/A |
| Privia Health Group, Inc. (PRVA)vs › | $2.57B | N/A | N/A | N/A | N/A |
| Precigen, Inc. (PGEN)vs › | $2.72B | N/A | N/A | N/A | N/A |
| AtriCure, Inc. (ATRC)vs › | $2.77B | N/A | N/A | N/A | N/A |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.51B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.80B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
